Directa Plus – argues “continues to perform strongly”. Does it?
Writing on company which describes itself as “a leading producer and supplier of graphene nanoplatelets based products for use in consumer and industrial markets” Directa Plus (DCTA) earlier this week, I noted US patents development and “generating considerable interest”, but what about the financials?. So what of now a “pleased to provide… trading update ahead of the announcement of its half year results for the six months to 30 June 2022 on 29 September”?
- By Steve Moore
- 2022-09-01 16:29:36